MECHANISM OF ESTROGEN ACTIVATION OF C-MYC ONCOGENE EXPRESSION

被引:1
|
作者
DUBIK, D [1 ]
SHIU, RPC [1 ]
机构
[1] UNIV MANITOBA, DEPT PHYSIOL, WINNIPEG R3E 0W3, MANITOBA, CANADA
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The estrogen receptor complex is a known trans-acting factor that regulates transcription of specific genes through an interaction with a specific estrogen-responsive cis-acting element (ERE). In previous studies we have shown that in estrogen-responsive human breast cancer cells estrogen rapidly activates c-myc expression. This activated expression occurs through enhanced transcription and does not require the synthesis of new protein intermediates; therefore, an ERE is present in the human c-myc gene regulatory region. To localize the ERE, constructs containing varying lengths of the c-myc 5'-flanking region ranging from - 2327 to + 25 (relative to the PI promoter) placed adjacent to the chloramphenicol acetyl transferase reporter gene (CAT) were prepared. They were used in transient transfection studies in MCF-7 and HeLa cells co-transfected with an estrogen receptor expression vector. These studies reveal that at] constructs containing the P2 promoter region exhibited estrogen-regulated CAT expression and that a 116-bp region upstream and encompassing the P2 TATA box is necessary for this activity. Analysis of this 116-bp region failed to identify a cis-acting element with sequences resembling the consensus ERE; however, co-transfection studies with mutant estrogen receptor expression vectors showed that the DNA-binding domain of the receptor is essential for estrogen-regulated CAT gene expression. We have also observed that anti-estrogen receptor complexes can weakly trans-activate from this 116-bp region but fail to do so from the ERE-containing ApoVLDLII-CAT construct. To explain these results we propose a new mechanism of estrogen trans-activation in the c-myc gene promoter.
引用
收藏
页码:1587 / 1594
页数:8
相关论文
共 50 条
  • [21] C-MYC ONCOGENE EXPRESSION IS NOT THE TARGET FOR VERAPAMILS ANTIPROLIFERATIVE EFFECT
    HUBER, KR
    SCHMIDT, WF
    NEUBERG, RW
    ETTINGER, RS
    CLINICAL RESEARCH, 1988, 36 (01): : A69 - A69
  • [22] C-MYC ONCOGENE EXPRESSION AND CLINICAL OUTCOME IN CARCINOMA OF THE CERVIX
    SOWANI, A
    ONG, G
    DISCHE, S
    QUINN, C
    WHITE, J
    SOUTTER, P
    WAXMAN, J
    SIKORA, K
    MOLECULAR AND CELLULAR PROBES, 1989, 3 (02) : 117 - 123
  • [23] The clinical significance of c-myc oncogene expression in melanomas of the scalp
    Chana, JS
    Grover, R
    Wilson, GD
    Hudson, DA
    Forders, M
    Sanders, R
    Grobbelaar, AO
    BRITISH JOURNAL OF PLASTIC SURGERY, 1998, 51 (03): : 191 - 194
  • [24] Mechanism of c-Myc autoregulation: c-Myc activates the transcription of Mxi which downregulates c-Myc expression.
    Mattioli, M
    Wu, KJ
    Dalla-Favera, R
    BLOOD, 2000, 96 (11) : 701A - 701A
  • [25] THE C-MYC ONCOGENE IN TUMOR PROGRESSION
    GARTE, SJ
    CRITICAL REVIEWS IN ONCOGENESIS, 1993, 4 (04): : 435 - 449
  • [26] Hepatic activation of c-myc oncogene by native and peroxidized linoleic acid
    Rohr-Udilova, Nataliya
    Berger, Heidi
    Hayden, Hubert
    Huber, Klaus
    Stolze, Klaus
    Murkovic, Michael
    Grasl-Kraupp, Bettina
    Peck-Radosavljevic, Markus
    WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (15-16) : A38 - A39
  • [27] SPECIFIC ALTERATIONS IN RADIATION-INDUCED ACTIVATION OF THE C-MYC ONCOGENE
    SAWEY, MJ
    BURNS, FJ
    GARTE, SJ
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 147 - 147
  • [28] HEPATIC ACTIVATION OF C-MYC ONCOGENE BY NATIVE AND PEROXIDIZED LINOLEIC ACID
    Rohr-Udilova, Nataliya
    Berger, Heidi
    Hayden, Hubert
    Huber, Wolfgang W.
    Murkovic, Michael
    Stolze, Klaus
    Peck-Radosavljevic, Markus
    HEPATOLOGY, 2009, 50 (04) : 1158A - 1158A
  • [29] TRANSCRIPTIONAL ACTIVATION OF THE TRANSLOCATED C-MYC ONCOGENE IN BURKITT-LYMPHOMA
    ERIKSON, J
    ARRUSHDI, A
    DRWINGA, HL
    NOWELL, PC
    CROCE, CM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (03): : 820 - 824
  • [30] PRIVILEGED PARTNERS OF THE C-MYC ONCOGENE
    LACAZEMASMONTEIL, T
    M S-MEDECINE SCIENCES, 1991, 7 (08): : 865 - 866